CDw75/ST6GAL1 Antibody (ZB55): sc-20063
- CDw75/ST6GAL1 Antibody (ZB55) is a mouse monoclonal IgM κ, cited in 1 publications, provided at 200 µg/ml
- raised against a CD32 peptide
- recommended for detection of CDw75 of human origin by IF, IHC(P) and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CDw75/ST6GAL1 Antibody (ZB55). This work is in progress.
QUICK LINKS
SEE ALSO...
ST6GAL1 Antibody (ZB55) is a mouse monoclonal IgM antibody that detects ST6GAL1 in human samples through applications such as immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). ST6GAL1, also known as CD75, is a crucial sialyltransferase that plays a significant role in the modification of glycoproteins and glycolipids, which is essential for various cellular processes, including tumorigenesis and metastasis. Anti-ST6GAL1 antibody (ZB55) recognizes an enzyme that catalyzes the transfer of sialic acid to carbohydrate chains, leading to the formation of sialylated antigens that serve as important cell-surface carbohydrate determinants. ST6GAL1′s presence in the Golgi apparatus and secretion into the extracellular fluid highlight a pivotal role in generating antigens, such as CDw75, which is primarily expressed on B and T cells. The upregulation of CDw75 in B-cell leukemias suggests that ST6GAL1 may have implications in cancer biology, making ST6GAL1 a valuable target for research into tumor development and immune response. ST6GAL1 monoclonal antibody (ZB55) facilitates the study of these critical processes, serving as an essential tool for researchers investigating the complex roles of sialylation in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CDw75/ST6GAL1 Antibody (ZB55) References:
- ST6GAL1 negatively regulates monocyte transendothelial migration and atherosclerosis development. | Zhang, J., et al. 2018. Biochem Biophys Res Commun. 500: 249-255. PMID: 29654763
- Plasma ST6GAL1 regulates IgG sialylation to control IgA nephropathy progression. | Liu, Y., et al. 2021. Ther Adv Chronic Dis. 12: 20406223211048644. PMID: 34729155
- Extracellular ST6GAL1 regulates monocyte-macrophage development and survival. | Rusiniak, ME., et al. 2022. Glycobiology. 32: 701-711. PMID: 35661210
- Extracellular sialyltransferase st6gal1 in breast tumor cell growth and invasiveness. | Hait, NC., et al. 2022. Cancer Gene Ther. 29: 1662-1675. PMID: 35676533
- ST6Gal1 in plasma is dispensable for IgG sialylation. | Oswald, DM., et al. 2022. Glycobiology. 32: 803-813. PMID: 35746897
- Downregulation of ST6GAL1 Promotes Liver Inflammation and Predicts Adverse Prognosis in Hepatocellular Carcinoma. | Liu, R., et al. 2022. J Inflamm Res. 15: 5801-5814. PMID: 36238765
- ST6GAL1 inhibits metastasis of hepatocellular carcinoma via modulating sialylation of MCAM on cell surface. | Zou, X., et al. 2023. Oncogene. 42: 516-529. PMID: 36528750
- Role of the ST6GAL1 sialyltransferase in regulating ovarian cancer cell metabolism. | Jones, RB., et al. 2023. Glycobiology. 33: 626-636. PMID: 37364046
- Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics. | Ankenbauer, KE., et al. 2023. J Biol Chem. 299: 105217. PMID: 37660914
- Role of ST6GAL1 in Thyroid Cancers: Insights from Tissue Analysis and Genomic Datasets. | Gunjača, I., et al. 2023. Int J Mol Sci. 24: PMID: 38003522
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CDw75/ST6GAL1 Antibody (ZB55) | sc-20063 | 200 µg/ml | $322.00 | |||
CDw75/ST6GAL1 Antibody (ZB55) FITC | sc-20063 FITC | 200 µg/ml | $336.00 | |||
CDw75/ST6GAL1 Antibody (ZB55) PE | sc-20063 PE | 200 µg/ml | $349.00 |